Trandolapril
Ace Inhibitors, Plain
Sold as MAVIK
- Drug class
- Ace Inhibitors, Plain
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 42
- FDA reports (12 mo)
- 100
Overview
Trandolapril is an active pharmaceutical ingredient in the Ace Inhibitors, Plain group (C09AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 31 | March 22, 2025 |
| GB United Kingdom | MHRA | 9 | May 15, 2026 |
| US United States | FDA | 2 | April 18, 2024 |
CACanada· Health Canada
31 products
Uses
40 MAVIK® Product Monograph Page 3 of 43 Date of Revision: August 19, 2019 and Control No. 5 mg, 1 mg, 2 mg and 4 mg erythrosine, gelatin, iron oxides and hydroxides, lactose, maize starch, povidone, sodium lauryl sulphate, sodium stearyl fumarate, titanium dioxide.
INDICATIONS AND CLINICAL USE MAVIK® (trandolapril) is indicated for: ● Treatment of Mild to Moderate Essential Hypertension. It may be used alone or in association with thiazide diuretics. The safety and efficacy of MAVIK® in patients with renovascular hypertension has not been established, therefore its use in these conditions is not recommended.
● Treatment Following Acute Myocardial Infarction in clinically stable patients with left ventricular dysfunction, with or without symptoms of heart failure, to improve survival and reduce hospitalizations for heart failure. Sufficient experience in the treatment of patients with severe heart failure [(New York Heart Association (NYHA) Class IV] immediately after myocardial infarction is not yet available.
GBUnited Kingdom· MHRA
9 products
Uses
Mild or moderate hypertension. Left ventricular dysfunction after acute myocardial infarction.
How to take
USUnited States· FDA
2 products
Uses
INDICATIONS AND USAGE
Hypertension Trandolapril tablets USP are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets USP are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction.
Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see CLINICAL PHARMACOLOGY -Heart Failure or Left-Ventricular Dysfunction Post Myocardial Infarction for details of the survival trial).
Drug interactions
Known interactions involving Trandolapril. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 345. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02231457 · revised March 22, 2025
- [2]MHRA (UK) · PL001420939 · revised May 1, 2026
- [3]FDA DailyMed · 0107d19a-b43a-4a… · revised April 18, 2024 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.